HOUSTON, Sept. 14, 2026 (GLOBE NEWSWIRE) — Neutra Corp (OTC: NTRR), a company focused on health, wellness, and life sciences, today announced that its wholly owned clinical research Site Management Organization (SMO) subsidiary, Neutra Life Sciences (“NLS”), has expanded its 2026 industry conference schedule with the addition of three new events — Partnership with Sites, DPharm: Disruptive Innovations to Advance Clinical Trials, and Fall Clinical – Dermatology — as part of its ongoing strategy to deepen sponsor and CRO relationships and expand trial opportunities across its growing site network.
The additions build on NLS’s previously announced attendance at the SCRS Global Site Solutions Summit and Obesity Week 2026, bringing the Company’s confirmed 2026 conference schedule to five events. Neutra Life Sciences will use each engagement to connect directly with sponsors and CROs, showcase its multi-site network, and identify new trial and partnership opportunities for its investigative sites.
“Every conference on this schedule is about the same goal — putting Neutra Life Sciences in front of the sponsors and CROs who can bring new trials into our network,” said Sydney Jim, President and CEO of Neutra Corp. “Adding Partnership with Sites, DPharm, and Fall Clinical – Dermatology gives us more touchpoints with the people who decide where trials go, and we intend to leave each one with new relationships and new opportunities for our sites.”
Industry Conference Presence
As part of its ongoing outreach strategy, Neutra Life Sciences will attend the following industry conferences in 2026:
Partnership with Sites (September 14, 2026) – Partnership with Sites brings together clinical trial site leaders, sponsors, and CROs to explore new collaboration models across the site management landscape. Neutra Life Sciences will attend to connect with sponsors and CROs and highlight its growing multi-site network.
DPharm: Disruptive Innovations to Advance Clinical Trials (September 15–16, 2026) – DPharm convenes pharmaceutical, biotech, and clinical operations leaders to discuss innovative approaches to trial design and execution. Neutra Life Sciences will attend to engage with sponsors and CROs exploring new site partnership models.
Fall Clinical – Dermatology (October 8–11, 2026) – Fall Clinical is a leading dermatology conference bringing together clinicians, researchers, and industry partners. Neutra Life Sciences will attend to strengthen relationships with dermatology sponsors and CROs and showcase its investigative site network in the specialty.
SCRS Global Site Solutions Summit (October 15–18, 2026) – The Society for Clinical Research Sites (SCRS) Global Summit is the premier gathering of clinical research site professionals and industry stakeholders. Neutra Life Sciences will attend to engage with sponsors, CROs, and fellow site operators, showcase its growing multi-site network, and identify new trial and partnership opportunities.
Obesity Week 2026 (November 14–17, 2026) – Obesity Week is the largest international conference dedicated to the science and treatment of obesity, convening leading researchers, clinicians, and industry professionals. Neutra Life Sciences’ attendance underscores its commitment to expanding its therapeutic area footprint and engaging sponsors and CROs active in metabolic and obesity-related clinical research.
Site Update: Women’s Health Care Center of Baytown
Neutra Life Sciences has also successfully started operations at Women’s Health Care Center of Baytown, the clinical research site partnership the Company announced in June 2026. The site is now successfully enrolling patients in two indications — early pregnancy and breast cancer screening — adding to NLS’s growing base of active investigative sites.
For more information about partnering with Neutra Life Sciences, please contact:
www.neutralifesciences.com
About Neutra Corp
Neutra Corp is a health and wellness company dedicated to advancing life sciences, clinical research, and innovative consumer health solutions. With a diversified portfolio, Neutra Corp focuses on life sciences technology, clinical research, and high-quality wellness products designed to support overall health and well-being.
Committed to empowering individuals with the tools and knowledge needed to make informed healthcare decisions, Neutra Corp integrates cutting-edge research with real-world applications. Its expansion into life sciences and clinical research reinforces its mission to drive innovation in healthcare, while its wellness product line provides natural solutions for consumers seeking alternative wellness options.
Through strategic acquisitions and partnerships, Neutra Corp continues to grow its impact in the life sciences and health sectors, bridging the gap between research, technology, and consumer wellness. For investing, information and performance data, please visit https://www.neutrainc.com
About Neutra Life Sciences
Neutra Life Sciences is a clinical research site management organization that is comprised of multiple clinical research sites across various specialties. Their network of Principal Investigators are passionate about advancing medical research and improving healthcare outcomes.
Neutra Life Sciences is dedicated to transforming clinical research through a patient-centric approach. They specialize in optimizing trial operations, enhancing patient experiences, and delivering high-quality data to advance medical innovation.
Their mission is to bridge the gap between cutting-edge clinical trials and the communities that need them most. By fostering strong partnerships with investigators, sponsors, and CROs, we ensure efficient study execution while prioritizing patient safety, comfort, and engagement.
With a team of experienced research professionals, Neutra Life Sciences seamlessly integrates proprietary Standard Operating Procedures (SOPs) with industry best practices to ensure efficiency, compliance, and the highest standards of patient care in every clinical trial we manage. They have an unwavering commitment to excellence, integrity, and innovation drives us to make a meaningful impact in clinical research—one patient at a time.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, a description of anyone’s past success, either financial or strategic, is no guarantee of success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.
Contacts
Neutra Corp.
Sydney Jim, 307-228-1488
President and CEO
[email protected]
